Announcement
Blog
Podcast
Press Release

Brighton Park’s Calen Angert Named to GrowthCap’s 2023 List of Top Healthcare Investors

With

We are excited to share that Calen Angert, Partner and Head of the Healthcare Group, has been named by GrowthCap as one of the Top 25 Healthcare Investors of 2023. The annual list recognizes leading individual investors in the healthcare sector who have demonstrated exceptional performance in the areas of investment selection, value creation, and ESG engagement.

As a seasoned investment professional with a deep understanding of the healthcare landscape, Calen has been critical in accelerating the firm’s investments in Healthcare Information Technology (HCIT) and healthcare services. His expertise has been invaluable in expanding the Brighton Park portfolio and partnering with management teams to help drive growth and build lasting value. Calen has made tremendous contributions to Brighton Park’s founder-friendly partnership style, collaborative culture, and growth-oriented investment philosophy through supporting the firm’s portfolio of leading healthcare businesses, including XSOLIS, Relatient, and Indegene, as well as identifying new investment opportunities across the healthcare ecosystem.

GrowthCap curated the list through a detailed evaluation of several hundred nominations received by portfolio company CEOs, firm colleagues, and peers in the investment and healthcare industries. GrowthCap adequately assessed and selected awardees based on their deal experience and track record, strategic and operational capabilities provided to portfolio companies, unique and differentiated attributes, as well as their contributions to ESG, DEI, charitable work, and overall industry advancement. GrowthCap also supplemented its analysis of the nominations submitted with its own proprietary research.

Read more about Brighton Park’s Calen Angert and the other honorees here.

*This award may have been derived from the subjective criteria of the party conferring the award and from a limited pool of participants. Brighton Park Capital has paid a fee for the nomination for and/or publication of this award. There can be no assurance that other providers or surveys would reach the same conclusion as the foregoing.